ProShare Advisors LLC lessened its stake in NantHealth Inc (NYSE:NH) by 2.2% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 64,029 shares of the company’s stock after selling 1,443 shares during the quarter. ProShare Advisors LLC owned about 0.05% of NantHealth worth $271,000 at the end of the most recent reporting period.
A number of other hedge funds also recently bought and sold shares of the stock. TIAA CREF Investment Management LLC raised its stake in NantHealth by 68.6% during the first quarter. TIAA CREF Investment Management LLC now owns 20,200 shares of the company’s stock worth $100,000 after acquiring an additional 8,217 shares in the last quarter. Alliancebernstein L.P. acquired a new position in shares of NantHealth in the second quarter valued at approximately $102,000. Bank of America Corp DE increased its stake in shares of NantHealth by 366.4% in the first quarter. Bank of America Corp DE now owns 25,069 shares of the company’s stock valued at $125,000 after buying an additional 19,694 shares during the period. Teachers Advisors LLC increased its stake in shares of NantHealth by 351.8% in the second quarter. Teachers Advisors LLC now owns 31,578 shares of the company’s stock valued at $134,000 after buying an additional 24,588 shares during the period. Finally, Bank of New York Mellon Corp increased its stake in shares of NantHealth by 194.9% in the second quarter. Bank of New York Mellon Corp now owns 44,849 shares of the company’s stock valued at $190,000 after buying an additional 29,639 shares during the period.
In other news, COO Ronald Allen Louks sold 26,820 shares of the business’s stock in a transaction that occurred on Friday, October 6th. The stock was sold at an average price of $4.28, for a total transaction of $114,789.60. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.
NH has been the subject of several recent research reports. Jefferies Group LLC reaffirmed a “buy” rating and issued a $5.50 price objective (down previously from $8.00) on shares of NantHealth in a research note on Monday, June 19th. Canaccord Genuity reaffirmed a “buy” rating and issued a $6.00 price objective (down previously from $8.00) on shares of NantHealth in a research note on Monday, August 21st. BidaskClub raised NantHealth from a “strong sell” rating to a “sell” rating in a research note on Friday, September 8th. Finally, Zacks Investment Research raised NantHealth from a “hold” rating to a “buy” rating and set a $4.50 price objective for the company in a research note on Thursday. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $8.30.
COPYRIGHT VIOLATION NOTICE: “ProShare Advisors LLC Has $271,000 Position in NantHealth Inc (NH)” was originally reported by Stock Observer and is the property of of Stock Observer. If you are viewing this article on another publication, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.thestockobserver.com/2017/10/13/proshare-advisors-llc-has-271000-position-in-nanthealth-inc-nh.html.
NantHealth (NYSE:NH) last announced its quarterly earnings results on Thursday, August 10th. The company reported ($0.58) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.26) by ($0.32). The company had revenue of $26.23 million during the quarter, compared to analysts’ expectations of $31.28 million. NantHealth had a negative return on equity of 83.97% and a negative net margin of 267.11%. NantHealth’s revenue for the quarter was down 16.7% on a year-over-year basis. During the same period last year, the firm earned ($0.15) earnings per share.
NantHealth, Inc is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples.
Receive News & Ratings for NantHealth Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth Inc and related companies with MarketBeat.com's FREE daily email newsletter.